{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:01:25Z","timestamp":1789052485413,"version":"build-2803163510"},"reference-count":37,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00283"],"award-info":[{"award-number":["PI20\/00283"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CERCA Programme\/Generalitat de Catalunya","award":["PI20\/00283"],"award-info":[{"award-number":["PI20\/00283"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Immunotherapy with immune checkpoint inhibitors (ICIs) have been reported to induce de novo or exacerbate pre-existing Myasthenia Gravis (MG). We present a single center case series of patients who developed an immune-related myasthenia gravis (irMG) related with ICIs. We performed a retrospective chart review of the electronic medical records between 1 September 2017 and 2022. We report the clinical features, presentation forms, diagnostic workflows, general management and outcomes of six patients who received ICIs for different solid organ malignancies and developed an irMG frequently overlapping with immune-related myocarditis and\/or myositis. The aim of the article is to describe the clinical features, treatment and outcomes of this challenging and potentially life-threating syndrome, comparing our data with those described in the literature. Differences between irMG and classic MG are highlighted.<\/jats:p>","DOI":"10.3390\/jcm12010130","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T02:53:11Z","timestamp":1672109591000},"page":"130","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series"],"prefix":"10.3390","volume":"12","author":[{"given":"Carla","family":"Marco","sequence":"first","affiliation":[{"name":"Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), 08908 L\u2019Hospitalet de Llobregat, Spain"},{"name":"Neuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge, 08907 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sim\u00f3","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), 08908 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Alemany","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), 08908 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"Neuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge, 08907 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Neuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge, 08907 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Vilari\u00f1o","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), 08908 L\u2019Hospitalet de Llobregat, Spain"},{"name":"Department of Oncology, Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), 08908 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariona","family":"Calvo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), 08908 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Mart\u00edn-Liberal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), 08908 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0238-3319","authenticated-orcid":false,"given":"Jes\u00fas","family":"Brenes","sequence":"additional","affiliation":[{"name":"Department of Oncology, Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), 08908 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Sabater-Riera","sequence":"additional","affiliation":[{"name":"Critical Care Department, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Hospital Universitari de Bellvitge, 08908 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-5047","authenticated-orcid":false,"given":"Jordi","family":"Bruna","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), 08908 L\u2019Hospitalet de Llobregat, Spain"},{"name":"Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences (UAB), 08193 Cerdanyola del Vall\u00e8s, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3194-9406","authenticated-orcid":false,"given":"Roser","family":"Velasco","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), 08908 L\u2019Hospitalet de Llobregat, Spain"},{"name":"Neuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge, 08907 L\u2019Hospitalet de Llobregat, Spain"},{"name":"Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences (UAB), 08193 Cerdanyola del Vall\u00e8s, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Vaddepally, R.K., Kharel, P., Pandey, R., Garje, R., and Chandra, A.B. (2020). Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers, 12.","DOI":"10.3390\/cancers12030738"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the Percentage of US Patients with Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"824511","DOI":"10.3389\/fonc.2022.824511","article-title":"Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data","volume":"12","author":"Ruggiero","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"(2022). FDA approves anti-LAG3 checkpoint. Nat. Biotechnol., 40, 625.","DOI":"10.1038\/s41587-022-01331-0"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1111\/jns.12339","article-title":"Immune Checkpoint Inhibitors-induced Neuromuscular Toxicity: From Pathogenesis to Treatment","volume":"24","author":"Psimaras","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological Adverse Events Associated with Immune Checkpoint Inhibitor: A Retrospective, Pharmacovigilance Study Using FAERS Database","volume":"152","author":"Mikami","year":"2021","journal-title":"J. Neurooncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic Complications of Immune Checkpoint Inhibitors","volume":"137","author":"Fellner","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/jns.12371","article-title":"Incidence and Characteristics of Neurotoxicity in Immune Checkpoint Inhibitors with Focus on Neuromuscular Events: Experience beyond the Clinical Trials","volume":"25","author":"Bruna","year":"2020","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s10072-022-05920-4","article-title":"Neurotoxicity and Safety of the Rechallenge of Immune Checkpoint Inhibitors: A Growing Issue in Neuro-Oncology Practice","volume":"43","author":"Velasco","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","article-title":"Neurological and Related Adverse Events in Immune Checkpoint Inhibitors: A Pharmacovigilance Study from the Japanese Adverse Drug Event Report Database","volume":"145","author":"Sato","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-Related Myasthenia Gravis with Myositis and Myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune Checkpoint Inhibitor\u2013Induced Myocarditis with Myositis\/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1111\/ajco.13442","article-title":"Immune Checkpoint Inhibitor-associated Myositis and Myasthenia Gravis Overlap: Understanding the Diversity in a Case Series","volume":"17","author":"Wong","year":"2021","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e002886","DOI":"10.1136\/jitc-2021-002886","article-title":"Effect of a Multidisciplinary Severe Immunotherapy Complications Service on Outcomes for Patients Receiving Immune Checkpoint Inhibitor Therapy for Cancer","volume":"9","author":"Zubiri","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e002890","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus Disease Definitions for Neurologic Immune-Related Adverse Events of Immune Checkpoint Inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Jaretzki, A., Barohn, R.J., Ernstoff, R.M., Kaminski, H.J., Keesey, J.C., Penn, A.S., and Sanders, D.B. (2000). Myasthenia Gravis: Recommendations for Clinical Research Standards. Neurology, 55, 16\u201323.","DOI":"10.1212\/WNL.55.1.16"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"CTCAE versi\u00f3n 5.0. Evaluaci\u00f3n de la gravedad de los eventos adversos dermatol\u00f3gicos de las terapias antineopl\u00e1sicas","volume":"112","author":"Santana","year":"2021","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/B978-0-444-64142-7.00055-2","article-title":"Clinical Neurophysiology of Neuromuscular Junction Disease","volume":"Volume 161","author":"Juel","year":"2019","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune Checkpoint Inhibitor Related Myasthenia Gravis: Single Center Experience and Systematic Review of the Literature","volume":"7","author":"Safa","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"858628","DOI":"10.3389\/fneur.2022.858628","article-title":"Association Between Clinical Factors and Result of Immune Checkpoint Inhibitor Related Myasthenia Gravis: A Single Center Experience and Systematic Review","volume":"13","author":"Shi","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune Checkpoint Inhibitor-Induced Myasthenia Gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Dresser, L., Wlodarski, R., Rezania, K., and Soliven, B. (2021). Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. JCM, 10.","DOI":"10.3390\/jcm10112235"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed Immune-Related Adverse Events with Anti-PD-1-Based Immunotherapy in Melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies: Systematic Review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/mus.25615","article-title":"Abnormal Spontaneous Activity on Needle Electromyography in Myasthenia Gravis: Abnormal Activity on Needle EMG in MG","volume":"56","author":"Kannaditharayil","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ensci.2018.11.024","article-title":"Reversible Spontaneous EMG Activity during Myasthenic Crisis: Two Case Reports","volume":"14","author":"Tsironis","year":"2019","journal-title":"eNeurologicalSci"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"JCO"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00415-021-10870-6","article-title":"How to Diagnose and Manage Neurological Toxicities of Immune Checkpoint Inhibitors: An Update","volume":"269","author":"Vogrig","year":"2022","journal-title":"J. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied Phenotypes and Management of Immune Checkpoint Inhibitor-Associated Neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic Toxicity Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study","volume":"7","author":"Johnson","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/130\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:49:57Z","timestamp":1760147397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["jcm12010130"],"URL":"https:\/\/doi.org\/10.3390\/jcm12010130","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,24]]}}}